Hepatitis B, Chronic Clinical Trial
— SALMONSOfficial title:
A Prospective Study to Investigate the Relationship Between Hepatitis B Surface Antigen (HBsAg) Loss and the Dynamics in Host and Viral Markers After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment in Chronic Hepatitis B E-antigen Negative Patients With Low On-treatment HBsAg Level
Verified date | October 2022 |
Source | Janssen Pharmaceutica N.V., Belgium |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the incidence of participants who reach hepatitis B surface antigen (HBsAg) seroclearance after discontinuing nucleos(t)ide analog (NA) therapy in participants with HBsAg less than or equal to (<=) 100 international units per milliliter (IU/mL) and participants with HBsAg greater than (>) 100 IU/mL to <= 500 IU/mL at baseline.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 28, 2025 |
Est. primary completion date | August 25, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Medically stable on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening and during the pre-biopsy assessments. If the results of the serum chemistry panel including liver enzymes, blood coagulation, other specific tests, or hematology are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study (in consultation with sponsor) - Hepatitis B surface antigen (HBsAg) less than or equal to (<=) 500 International units per milliliters (IU/mL) (and greater than [>] 5 IU/mL) at screening - Hepatitis B e antigen (HBeAg) less than (<) lower limit of quantification and hepatitis B e antibody (HBeAb) positive at screening - Normal liver ultrasound (at screening or within 3 months before screening [documented evidence]) - Participants must have a body mass index between 18.0 and 35.0 Kilograms per meter square (kg/m^2), extremes included Exclusion Criteria: - History of or signs of cirrhosis or portal hypertension (absence of nodules, no smooth liver contour, no normal portal vein, spleen size greater than or equal to [>=] 12 centimeters [cm]) or signs of hepatocellular carcinoma (HCC) or clinically relevant renal abnormalities on an abdominal ultrasound performed within 3 months prior to screening (based on documented evidence, if available) or at the time of screening. In case of suspicious findings on conventional ultrasound the participant may still be eligible if HCC or clinically relevant renal abnormalities have been ruled out by a more specific imaging procedure (contrast enhanced ultrasound, computed tomography [CT] or magnetic resonance imaging [MRI]) - Participant's refusal to accept blood transfusions - Participants with clinically relevant drug or alcohol abuse within 12 months before screening - Received an investigational intervention or used an invasive investigational medical device within 3 months before the planned enrollment or is currently enrolled in an investigational study - Participants of Asian descent |
Country | Name | City | State |
---|---|---|---|
Denmark | Sygehus Lillebælt - Kolding Sygehus | Kolding | |
Denmark | Odense Universitets Hospital | Odense | |
Denmark | Sjællands University hospital | Roskilde | |
France | Hôpital Avicenne | Bobigny | |
France | CHU Grenoble | La Tronche | |
France | Hopital de La Croix Rousse | Lyon | |
France | Hopital Pontchaillou | Rennes cedex 9 | |
Germany | Universitatsklinikum Frankfurt | Frankfurt | |
Germany | Medizinische Hochschule Hannover | Hannover | |
Germany | Klinikum Sankt Georg Neurologie | Leipzig | |
Germany | Universitatsklinikum Leipzig | Leipzig | |
Germany | Eberhard Karls Universität Tübingen | Tübingen | |
Greece | G.H. of Athens Evangelismos | Athens | |
Greece | Laiko General Hospital of Athens | Athens | |
Greece | General Hospital of Thessaloniki Ippokrateio | Thessaloniki | |
Italy | ASST Spedali Civili di Brescia | Brescia | |
Italy | Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia | Foggia | |
Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milano | |
Italy | Azienda Ospedaliero-Universitaria di Modena, Ospedale di Baggiovara | Modena | |
Italy | Azienda Ospedaliero Universitaria Pisana | Pisa | |
Italy | Casa Sollievo della Sofferenza | San Giovanni Rotondo | |
Italy | Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino | Torino | |
Portugal | Hosp. Sra. Da Oliveira - Guimaraes | Braga | |
Portugal | Centro Hospitalar e Universitario de Coimbra | Coimbra | |
Portugal | Centro Hospitalar de Lisboa Norte - Hospital Santa Maria | Lisboa | |
Portugal | Centro Hospitalar de Trás os Montes e Alto Douro- Vila Real | Vila Real | |
Spain | Hosp. Clinic I Provincial de Barcelona | Barcelona | |
Spain | Hosp. Del Mar | Barcelona | |
Spain | Hosp. Univ. Marques de Valdecilla | Santander | |
Spain | Hosp. Clinico Univ. de Valencia | València |
Lead Sponsor | Collaborator |
---|---|
Janssen Pharmaceutica N.V., Belgium |
Denmark, France, Germany, Greece, Italy, Portugal, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants with Hepatitis B Surface Antigen (HBsAg) Seroclearance After Discontinuation of Nucleos(t)ide Analog (NA) Treatment | Percentage of participants with HBsAg seroclearance after discontinuation of NA treatment will be reported. | At Week 24 | |
Primary | Percentage of Participants with HBsAg Seroclearance After Discontinuation of NA Treatment | Percentage of participants with HBsAg seroclearance after discontinuation of NA treatment will be reported. | At Week 48 | |
Primary | Percentage of Participants with HBsAg Seroclearance After Discontinuation of NA Treatment | Percentage of participants with HBsAg seroclearance after discontinuation of NA treatment will be reported. | At Week 96 | |
Secondary | Percentage of Participants with Flares | Percentage of participants with flares (virologic, biochemical, and clinical) measured by blood markers (such as HBsAg, hepatitis B virus deoxyribonucleic acid [HBV DNA], and alanine aminotransferase [ALT]) will be reported. | At Week 24, Week 48, and Week 96 | |
Secondary | Change from Baseline Over Time in HBsAg Level | Change from baseline over time in HBsAg level will be reported. | Baseline up to 96 weeks | |
Secondary | Change from Baseline Over Time in HBV DNA level | Change from baseline over time in HBV DNA level will be reported. | Baseline up to 96 weeks | |
Secondary | Time to Achieve First HBsAg Seroclearance | Time to achieve first HBsAg seroclearance will be reported. | Up to 96 weeks | |
Secondary | Percentage of Sustained Clinical Responders | Percentage of sustained clinical responders (those with HBsAg seroclearance) will be reported. | At Week 24, Week 48, and Week 96 | |
Secondary | Percentage of Participants with HBsAg Seroconversion | Percentage of participants with HBsAg seroconversion will be reported. | At Week 24, Week 48, and Week 96 | |
Secondary | Percentage of Participants with Serious Adverse Events (SAEs) | SAE is any untoward medical occurrence that results in any of the following conditions that is death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity. | Up to 96 weeks | |
Secondary | Percentage of Participants with Abnormalities in Clinical Laboratory Parameters | Percentage of participants with abnormalities in clinical laboratory parameters will be reported. | Up to 96 weeks | |
Secondary | Percentage of Participants Who Meet the NA Re-Treatment Criteria | Percentage of participants who meet the NA re-treatment criteria will be reported. | Up to 96 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03272009 -
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
|
Phase 1 | |
Recruiting |
NCT01456312 -
HBsAg Related Response Guided Therapy
|
Phase 4 | |
Terminated |
NCT01886300 -
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam
|
N/A | |
Completed |
NCT01023230 -
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
|
Phase 1 | |
Completed |
NCT00962975 -
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies
|
Phase 1 | |
Completed |
NCT00536263 -
PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)
|
Phase 3 | |
Terminated |
NCT00460850 -
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
|
Phase 4 | |
Completed |
NCT03681132 -
The Norwegian Nucleoside Analogue Stop Study
|
Phase 4 | |
Active, not recruiting |
NCT05473806 -
Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
|
Phase 4 | |
Withdrawn |
NCT01179594 -
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
|
Phase 4 | |
Recruiting |
NCT05057065 -
A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
|
||
Completed |
NCT04439539 -
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
|
Phase 2 | |
Withdrawn |
NCT03125213 -
A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects
|
Phase 2 | |
Active, not recruiting |
NCT04782375 -
Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B
|
Phase 4 | |
Completed |
NCT02693652 -
A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT04160897 -
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
|
||
Active, not recruiting |
NCT02588937 -
Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients
|
Phase 4 | |
Completed |
NCT02612506 -
Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT02327416 -
A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)
|
Phase 3 | |
Active, not recruiting |
NCT02267473 -
Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function
|